Study Methodology

Study Methodology

Data was collected on 938,586 urine toxicology tests conducted during routine patient clinic visits from January 2006 to January 2009. This data was retrospectively abstracted and, because a patient’s course of treatment was not altered by this abstraction, no patient consent was required.

Urine screening was performed using Ameritox Ltd.’s Rx GuardianSM process. Enzyme immunoassay or fluorescent polarization immunoassay testing are used as a screen for opiates, benzodiazepines, illicit drugs, and other related medications. If positive, these immunoassays are followed by gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry confirmatory testing, which provides additional accuracy and specificity in detecting the absence or presence of the patient’s prescribed medication(s), as well as the presence of nonprescribed or illicit medications.1,2

Patient demographic data, urine drug testing (UDT) results, urine pH, and specific gravity are then used to calculate a normalized patient result using a proprietary methodology offered by Ameritox, Ltd. This normalized patient result is compared to a set of expected ranges developed from tests of likely adherent patients to help the patient’s treating physician better assess whether their patients are taking their medication correctly. 3,4